Preclinical and Co-Clinical Core for Patient-Specific Therapeutics
Official title: Preclinical/Co-Clinical Section
Funded at Jackson Laboratory · NIH-11393944 · Data updated 2026-11-12
A program that tests new treatments for human diseases using mouse models made from patient data, with a strong emphasis on translating findings toward future patient care.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Jackson Laboratory NIH-funded |
| Lab location | 1 site (Bar Harbor, United States) |
| Project start | September 1, 2020 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $549,135 |
| NIH project number | 5U54OD030187-07 |
| Project ID | NIH-11393944 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients whose disease biology can be modeled in mouse systems may indirectly benefit through discoveries that inform future therapies and biomarker development.
✕Less likely to help
Current patients may not directly receive a treatment from this core, but their biological data and samples are used to advance future options.
What this research studies
This grant centers on creating and testing therapies in mouse models that reflect individual patients, built by our Disease Modeling Unit. It connects clinicians, patients, researchers, and foundations to gather patient samples and data, which then guide lab studies and biomarker discovery. When models show clear disease features, we collaborate with partners to design genome-based therapies like antisense oligonucleotides, gene edits, and RNAi tools, and also explore repurposed drugs. The project combines in vitro and in vivo testing to assemble a pre-IND package that could accelerate bringing effective treatments to people who need them. The Jackson Laboratory leads this work with clinical collaborators to bridge patient biology to potential therapies.
Why it matters
Potential benefit: If successful, the work could streamline the development of tailored therapies for specific patients and disease mechanisms, potentially shortening the path to clinical testing.
How similar studies have gone: Previous models linking patient data to mouse phenotypes have guided targeted therapies in other diseases, showing promise for this approach.
Where this research is happening
-
Jackson Laboratory
Bar Harbor, United States Active
Researchers
- Principal investigator: Lutz, Cathleen M — Jackson Laboratory
- Study coordinator: Lutz, Cathleen M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.